These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 29141265)

  • 1. [HBV-infections in Germany - health care costs in a real-life-setting].
    Stahmeyer JT; Becker H; Orlemann AL; Krauth C; Manns MP; Wedemeyer H
    Z Gastroenterol; 2017 Nov; 55(11):1103-1112. PubMed ID: 29141265
    [No Abstract]   [Full Text] [Related]  

  • 2. [Costs of guideline-based treatment of hepatitis B patients in Germany].
    Stahmeyer JT; Becker H; Heidelberger S; Wiebner B; Deterding K; Cornberg M; Manns MP; Krauth C; Wedemeyer H
    Z Gastroenterol; 2012 Aug; 50(8):745-52. PubMed ID: 22895902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The economic burden of hepatitis B in Germany.
    Harbarth S; Szucs T; Berger K; Jilg W
    Eur J Epidemiol; 2000 Feb; 16(2):173-7. PubMed ID: 10845268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost of treating hepatitis C in Germany: a retrospective multicenter analysis.
    Stahmeyer JT; Rossol S; Bert F; Antoni C; Demir M; Hinrichsen H; Hüppe D; Teuber G; Wiebner B; Wedemeyer H; Krauth C
    Eur J Gastroenterol Hepatol; 2014 Nov; 26(11):1278-85. PubMed ID: 25144493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Financial burden of hepatitis B-related diseases and factors influencing the costs in Shenzhen, China].
    Liang S; Zhang SX; Ma QS; Xiao HW; Lü QY; Xie X; Mei SJ; Hu DS; Zhou BP; Li B; Chen JF; Cui FQ; Wang FZ; Liang XF
    Zhonghua Liu Xing Bing Xue Za Zhi; 2010 Dec; 31(12):1340-5. PubMed ID: 21223660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes and costs of treating hepatitis C patients with second-generation direct-acting antivirals: results from the German Hepatitis C-Registry.
    Krüger K; Krauth C; Rossol S; Mauss S; Boeker KHW; Müller T; Klinker H; Pathil A; Heyne R; Stahmeyer JT;
    Eur J Gastroenterol Hepatol; 2019 Feb; 31(2):230-240. PubMed ID: 30325794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How big is the financial burden of hepatitis B to society? A cost-of-illness study of hepatitis B infection in Singapore.
    Ong SC; Lim SG; Li SC
    J Viral Hepat; 2009 Jan; 16(1):53-63. PubMed ID: 19192158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Socio-economical aspects, quality of life and state of knowledge in hepatitis B patients. Socio-economical aspects in hepatitis B].
    Niederau C; Fischer C; Kautz A
    Z Gastroenterol; 2007 May; 45(5):355-68. PubMed ID: 17503314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic burden of hepatitis B infection among patients with diabetes.
    Deshpande G; Klink AJ; Shenolikar R; Singer J; Eisenberg Lawrence DF; Krishnarajah G
    Hum Vaccin Immunother; 2016 May; 12(5):1132-40. PubMed ID: 27050021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-life costs of hepatitis C treatment.
    Helsper CW; Hellinga HL; van Essen GA; de Wit GA; Bonten MJ; van Erpecum KJ; Hoepelman AI; Richter C; de Wit NJ
    Neth J Med; 2012 Apr; 70(3):145-53. PubMed ID: 22516582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis B outbreak in a nursing home associated with reusable lancet devices for blood glucose monitoring, Northern Germany 2010.
    Diercke M; Monazahian M; Petermann H; Gerlich WH; Schüttler CG; Wend U; Dehnert M; Dreesman J
    J Med Virol; 2015 Apr; 87(4):583-8. PubMed ID: 25611818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Costs and outcomes of treating chronic hepatitis C patients in routine care - results from a nationwide multicenter trial.
    Stahmeyer JT; Krauth C; Bert F; Pfeiffer-Vornkahl H; Alshuth U; Hüppe D; Mauss S; Rossol S
    J Viral Hepat; 2016 Feb; 23(2):105-15. PubMed ID: 26411532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [On the economic burden of MRSA in Germany].
    Claus F; Sachse A; Ried W
    Gesundheitswesen; 2014 Dec; 76(12):800-6. PubMed ID: 25372655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No evidence of hepatitis B virus reactivation in patients with resolved infection treated with direct-acting antivirals for hepatitis C in a large real-world cohort.
    Mücke VT; Mücke MM; Peiffer KH; Weiler N; Welzel TM; Sarrazin C; Zeuzem S; Berger A; Vermehren J
    Aliment Pharmacol Ther; 2017 Aug; 46(4):432-439. PubMed ID: 28627791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Economic burden and related factors on inpatients with HBV-related diseases in Shandong province].
    Lü JJ; Li RP; Xu AQ; Zhang L; Song LZ; Yan BY; Ji F; Liu JY; Fang XQ; Wang Z; Zhu DW; Zhang GJ; Feng Y; Xiao ZK; Wang J
    Zhonghua Liu Xing Bing Xue Za Zhi; 2013 Mar; 34(3):267-72. PubMed ID: 23759235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results of a retrospective database analysis of drug utilization and costs for treatment of chronic hepatitis B virus infection in the northern Netherlands between 2000 and 2006.
    Tu HA; Bos JH; Woerdenbag HJ; Visser ST; Wilschut JC; van Assen S; de Jong-van den Berg LT; Postma MJ
    Clin Ther; 2010 Jan; 32(1):133-44. PubMed ID: 20171419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiology and economic importance of hepatitis B in the Federal Republic of Germany.
    Lange W; Masihi KN
    Postgrad Med J; 1987; 63 Suppl 2(741):21-6. PubMed ID: 3684845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Social/economic costs and health-related quality of life in patients with histiocytosis in Europe.
    Iskrov G; Astigarraga I; Stefanov R; López-Bastida J; Linertová R; Oliva-Moreno J; Serrano-Aguilar P; Posada-de-la-Paz M; Schieppati A; Taruscio D; Péntek M; von der Schulenburg JM; Kanavos P; Chevreul K; Persson U; Fattore G;
    Eur J Health Econ; 2016 Apr; 17 Suppl 1():67-78. PubMed ID: 27042831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of HAV and HBV infections and vaccination rates in patients with autoimmune liver diseases.
    Wörns MA; Teufel A; Kanzler S; Shrestha A; Victor A; Otto G; Lohse AW; Galle PR; Höhler T
    Am J Gastroenterol; 2008 Jan; 103(1):138-46. PubMed ID: 17970833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective analysis of total direct medical costs associated with hepatitis B patients with oral antiviral versus pegylated interferon therapy in Turkey.
    Altinbas A; Baser E; Burkan A; Ertugay E; Kariburyo MF; Baser O
    J Viral Hepat; 2014 Nov; 21(11):794-801. PubMed ID: 24548474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.